Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Ltd. has requested a trading halt on its securities pending the release of new data from its ADVENT-AML Phase 1B clinical trial. The halt is expected to last until the announcement is made or until the market opens on 19 May 2025, highlighting the potential significance of the upcoming data for the company’s operations and its stakeholders.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is primarily engaged in advancing clinical trials and research to bring new therapeutic solutions to market.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.33M
Learn more about CHM stock on TipRanks’ Stock Analysis page.